Overview
NICE is unable to make a recommendation on letermovir (Prevymis) for preventing cytomegalovirus infection after a kidney transplant in adults. This is because the company did not provide an evidence submission.
Last reviewed: 23 July 2025
Next review: We will review this decision if the company decides to make a submission.